Investors Information

 

EDAP TMS is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers.

NASDAQ: EDAP
$ 2.55
+0.21 (8.97%)

Day High: 2.59
Day Low:  2.26
Volume:    702,000
4:00 PM ET on
Nov 26, 2014

Delayed ~20 min., by eSignal.